Pr ecis: These results offer preclinical proof of concept for a novel type of bioactive STAT3 inhibitor that may be tractable for clinical development, addressing a longstanding challenge to target the broad array of cancers harboring constitutively activated STAT3. 
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Immunosurveillance by Antiangiogenesis: Tumor Growth Arrest by T Cell-Derived Thrombospondin-1 Pr ecis: These findings show how a cytokine secreted in the tumor microenvironment modulates EGF-induced invasion and heightens acquired drug resistance. Pr ecis: These findings illustrate the importance of a relatively small but unique class of human-specific microRNAs in tumor suppression, with possible implications in how to interpret in human cancer the action of the tumor suppressor FHIT, within which a new member of this microRNA class was found. 
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ABOUT THE COVER
Androgen receptor (AR) nuclear accumulation and transcriptional activity is critical for prostate cancer growth in hormone-naïve and castration resistant disease (CRPC). The taxanes, microtubule-stabilizing drugs, are widely used in the treatment of CRPC. The dynein motor protein to efficiently traffic AR to the nucleus utilizes microtubule dynamics. Taxane treatment interferes with this process and sequesters AR in the cytoplasm. AR splice variants are often expressed in CRPC and confer resistance to androgen deprivation therapies. Using confocal microscopy of prostate cancer cells expressing ARv567 (green) and the dynein accessory protein dynamitin (red) whose expression inhibits dynein-cargo binding, we show that ARv567 variant, similar to the AR wt, utilizes dynein motor protein and microtubules to efficiently translocate to the nucleus. For details, see article by Thadani-Mulero and colleagues on page 2270. To request permission to re-use all or part of this article, contact the AACR Publications Department at
